xB3-001 Potential Revenue EstimationsThe
September Corporate Presentation discusses the valuation of xB3-001 in some detail. The terms 1L, 2L, and 3L are used and are defined in
this article at
https://chemoth.com/. There are many cancer treatment resources on this site.
The September Corporate Presentation uses the 1L, 2L, and 3L terms as well as 2L+, representing treatments 2L, 3L and (rather rare) 4L treatments and 3L+ meaning 3L, 4L, etc.
As stated in recent press releases, Bioasis has been nailing down patent allowances (
China and
Japan). The presentation projects the entire world wide HER+ mBC (metastatic breast cancer) market and then uses 30% of that as the xB3-001 share.. The presentation gives potential xB3-001 1L and 2L+ revenues in the USA and then doubles those numbers to arrive at world wide (WW) projections.
The presentation indicates a total projected revenue for xB3-001 of USD 5.69 billion, very much in the ballpark of valuation discussions we've had over the years on this forum.
If Bioasis can achieve FDA breakthrough fast-tracking status for xB3-001 then these revenue projections could be achieved far sooner than normal, further enhancing the current value of xB3-001 and, likely, the value of the rest of the Bioasis pipeline drugs that also involve the transport of well-known and very successful therapeutics.
jdstox